Valeant bids $47B for Allergan

Share this article:
Valeant bids $47B for Allergan
Valeant bids $47B for Allergan

Valeant announced Tuesday it was making a $47 billion play to bring Allergan's cosmetics businesses in house. The unsolicited offer would merge the Allergan portfolio, which includes the blockbuster cosmetic / migraine / overactive bladder treatment Botox, cosmetic filler Juvederm, and the Natrelle breast implant business with Valeant's business which includes filler Restylane, which it picked up when it bought Medicis in 2012, and Bausch & Lomb's eye care business, which it scooped up in 2013, among others.

By Jefferies analyst David Steinberg's count, Valeant has made 23 public bids for companies in just four years.

Steinberg wrote in a Tuesday research note that Allergan's way out would include buying up a peer such as Jazz Pharma or Shire, which would make it unattractive to Valeant. He also noted in a Monday note, that Allergan may need an acquisition, regardless, since he anticipates overall sales will begin to slow down as of 2016.

Reports indicate that Valeant offered to buy Allergan a year and a half ago, but Allergan said no. Allergan said in a statement Tuesday that it is reviewing Valeant's proposal.

Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...